Tukysa (Tucatinib) Patent Expiration, LOE Window & CMS Spending

Tukysa (Tucatinib) by Pfizer: FDA Orange Book core substance LOE 2034-04-17 (last listed 2038-04-27), 0 AB generics, $189.6M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN213411 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-04-17
Last Listed Patent or Exclusivity Date2038-04-27
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$189.6M
2024 Medicare Part D Spend$139.4M
2024 Medicaid Spend$50.2M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 29.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.